MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584142 | Name: Befunolol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Befunolol is a beta blocker with intrinsic sympathomimetic activity used in the management of open-angle glaucoma. It also acts as a β adrenoreceptor partial agonist.

Chemical Structure

Befunolol
Befunolol
CAS#39552-01-7 (free base)

Theoretical Analysis

MedKoo Cat#: 584142

Name: Befunolol

CAS#: 39552-01-7 (free base)

Chemical Formula: C16H21NO4

Exact Mass: 291.1471

Molecular Weight: 291.34

Elemental Analysis: Chemical Formula: C16H21NO4 Exact Mass: 291.1471 Molecular Weight: 291.3470 Elemental Analysis: C, 65.96; H, 7.27; N, 4.81; O, 21.97

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
39543-79-8 (HCl) 39552-01-7 (free base)
Synonym
Befunolol
IUPAC/Chemical Name
7-(2-Hydroxy-3-(isopropylamino)propoxy)-2-benzofuranyl methyl ketone
InChi Key
ZPQPDBIHYCBNIG-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H21NO4/c1-10(2)17-8-13(19)9-20-14-6-4-5-12-7-15(11(3)18)21-16(12)14/h4-7,10,13,17,19H,8-9H2,1-3H3
SMILES Code
O=C(C1=CC2=CC=CC(OCC(O)CNC(C)C)=C2O1)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 291.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Koike K, Horinouchi T, Takayanagi I. Comparison of interactions of R(+)- and S(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in the microsomal fractions from guinea-pig ciliary body, right atria and trachea. Gen Pharmacol. 1994 Nov;25(7):1477-81. PubMed PMID: 7896063. 2: Maruyama Y, Tanonaka K, Niwa T, Takeo S. Beneficial effects of befunolol on post-hypoxic recovery of cardiac contractility and myocardial metabolism. Arzneimittelforschung. 1992 Dec;42(12):1423-9. PubMed PMID: 1363193. 3: Fusco R, Greco GM, Del Prete A, Caccavale A, Nieto G, Sabbatino S, Santilli F. Long-term effects of befunolol on the corneal endothelium and the consensual ophthalmotonic reaction. Clin Ther. 1992 Nov-Dec;14(6):785-90. PubMed PMID: 1363082. 4: Maruyama Y, Awaji T, Inoue M, Takeo S. Protective effects of befunolol on hypoxic respiration-induced alterations in myocardial energy metabolism of rats. Arzneimittelforschung. 1991 Oct;41(10):1022-6. PubMed PMID: 1799378. 5: Takayanagi I, Hagiwara H, Koike K, Hosokawa T, Kasuya Y. Effects of the R(+)- and S(-)-isomers of beta-adrenoceptor blockers with intrinsic sympathomimetic activity, befunolol and carteolol, on rabbit intraocular pressure. Can J Physiol Pharmacol. 1991 Aug;69(8):1243-5. PubMed PMID: 1685941. 6: Koike K, Hagiwara H, Takayanagi I. Comparison of interactions of R-(+)- and S-(-)-isomers of beta-adrenergic partial agonists, befunolol and carteolol, with high affinity site of beta-adrenoceptors in isolated rabbit ciliary body and guinea-pig taenia caeci. Can J Physiol Pharmacol. 1991 Jul;69(7):951-7. PubMed PMID: 1683268. 7: Maruyama Y, Awaji T, Inoue M, Takeo S. Metabolic profile of beta-adrenoceptor-blocking action of befunolol. Arch Int Pharmacodyn Ther. 1991 May-Jun;311:73-88. PubMed PMID: 1686392. 8: Imamura Y, Nozaki Y, Higuchi T, Otagiri M. Reactivity for prostaglandins and inhibition by nonsteridal anti-inflammatory drugs of rabbit liver befunolol reductase. Res Commun Chem Pathol Pharmacol. 1991 Jan;71(1):49-57. PubMed PMID: 2024065. 9: Höh H. [The local anesthetic effect and subjective tolerance of 0.5% befunolol and 1% pindolol in healthy eyes]. Klin Monbl Augenheilkd. 1990 Apr;196(4):219-24. German. PubMed PMID: 1971855. 10: Dorigo MT, Cerin O, Fracasso G, Altafini R. Cardiovascular effects of befunolol, betaxolol and timolol eye drops. Int J Clin Pharmacol Res. 1990;10(3):163-6. PubMed PMID: 1977708. 11: Takayanagi I, Ogishima M, Koike K. Thermodynamic analysis of beta-adrenergic partial agonists (befunolol and carteolol) interaction with low and high affinity binding sites of beta-adrenoceptors in guinea-pig taenia caecum. Gen Pharmacol. 1990;21(3):303-7. PubMed PMID: 1971246. 12: Takayanagi I, Koike K, Ogishima M. Interactions of R(+) and S(-) isomers of befunolol, a partial agonist with high and low affinity sites of beta-adrenoceptors in guinea-pig taenia caecum. Arch Int Pharmacodyn Ther. 1989 Jul-Aug;300:76-84. PubMed PMID: 2575890. 13: Wegener A, Maierhofer O, Heints M, Hockwin O. Testing a possible cocataractogenic potential of befunolol (Glauconex) with animal cataract models. J Ocul Pharmacol. 1989 Spring;5(1):45-50. PubMed PMID: 2715676. 14: Koike K, Tanaka H, Shigenobu K, Takayanagi I. Binding of [3H]befunolol to beta-adrenoceptors in cardiac muscles of fetal and neonatal rat. Can J Physiol Pharmacol. 1988 Jul;66(7):957-60. PubMed PMID: 2905631. 15: Koike K, Takayanagi I. Interactions of befunolol, a beta-adrenergic partial agonist, and its derivatives with high and low affinity sites in beta-adrenoceptors. J Pharmacobiodyn. 1987 Sep;10(9):494-8. PubMed PMID: 2893834. 16: Koike K, Takayanagi I. A beta-adrenergic partial agonist (befunolol) discriminates two different affinity sites. Jpn J Pharmacol. 1986 Oct;42(2):325-8. PubMed PMID: 2879061. 17: Hayasaka S, Nakazawa M, Mizuno K. Effects of pindolol, befunolol and melanin treated with adrenergic beta-blocking agents on lysosomal enzymes in bovine ciliary body and iris in vitro. Jpn J Ophthalmol. 1986;30(2):185-91. PubMed PMID: 2876118. 18: Takayanagi I, Koike K. A beta-adrenoceptor blocking agent, befunolol as a partial agonist in isolated organs. Gen Pharmacol. 1985;16(3):265-7. PubMed PMID: 2862092. 19: Merté HJ, Stryz JR. [Additional experience with the beta blocker befunolol (Glaukonex) in open-angle glaucoma over a period of 1 year]. Klin Monbl Augenheilkd. 1984 Apr;184(4):316-7. German. PubMed PMID: 6144813. 20: Merté HJ, Stryz JR. [Initial experience with the beta-blocker befunolol in the treatment of open-angle glaucoma in Europe]. Klin Monbl Augenheilkd. 1984 Jan;184(1):55-8. German. PubMed PMID: 6142975.

View History

Neogermbudine

Neogermbudine